Empery Digital Secures $25M Offering at Premium, Reduces Debt, and Navigates Proxy Contest

summarizeSummary

Empery Digital finalized a $25 million registered direct offering at a premium to market price, using proceeds for debt reduction and strategically exempting the transaction from its poison pill amidst an activist proxy contest.

check_boxKey Events

• Secures $25 Million Registered Direct Offering

  Empery Digital Inc. entered into a definitive agreement for a registered direct offering of 2,558,422 shares of common stock and pre-funded warrants to purchase 2,079,797 shares, along with accompanying common stock warrants to purchase 4,638,219 shares, raising approximately $25 million in gross proceeds.

• Offering Priced at a Premium

  The offering was priced at $5.39 per share (or pre-funded warrant), which is a significant premium to the current market price of $4.36, reflecting institutional confidence. The common warrants have an exercise price of $6.27.

• Debt Reduction and Balance Sheet Optimization

  Net proceeds, combined with cash on hand, will be used to reduce outstanding debt by approximately $40 million, including the full repayment of a $50 million Repo Facility and an incremental draw down of approximately $10 million on an existing credit facility.

• Strategic Exemption from Rights Agreement

  The Board of Directors declared the offering an 'Exempt Transaction' under the existing Rights Agreement (poison pill), preventing the triggering of anti-takeover provisions amidst an ongoing proxy contest with activist investor ATG Capital.

auto_awesomeAnalysis

This 8-K details a significant $25 million registered direct offering, which is crucial for Empery Digital Inc. given its ongoing activist investor situation. The offering is priced at $5.39 per share, a notable premium to the current market price of $4.36, reflecting institutional confidence. The proceeds will primarily be used to reduce outstanding debt by approximately $40 million, strengthening the company's balance sheet. Critically, the Board of Directors has exempted this transaction from the existing Rights Agreement (poison pill), allowing the capital raise to proceed without triggering anti-takeover provisions amidst a proxy contest launched by activist investor ATG Capital. This strategic maneuver provides capital while maintaining board control.